ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Neutrophil Extracellular Traps in COVID-19 Patients Correlates with Therapy, Disease Severity and Mortality

D. Kassina1, A. Gur'ev1,2, A. Martyanov3,4,5, A. Boldova4, M. Stepanyan6,4, O. An7,4, S. Tsarenko8, F. Ataullakhanov4,3,6, A. Sveshnikova6,3,4,7, A. Volkov2

1M.F. Vladimirsky Moscow Regional Clinical and Research Institute, Moscow, Russian Federation, 2Medtechnopark Ltd., Moscow, Russian Federation, 3NMRC PHOI named after Dmitry Rogachev, Moscow, Russian Federation, 4CTP PCP RAS, Moscow, Russian Federation, 5Emmanuel Institute for Biochemical Physics, Moscow, Russian Federation, 6Lomonosov Moscow State University, Physics Faculty, Moscow, Russian Federation, 7I.M. Sechenov First Moscow Medical University (Sechenov University), Moscow, Russian Federation, 8Moscow State Hospital 52, Moscow, Russian Federation

Abstract Number: OC 15.3

Meeting: ISTH 2021 Congress

Theme: COVID and Coagulation » COVID and Coagulation, Basic Science

Background: Neutrophil extracellular traps (NETs) are suggested to be the key driver in COVID-19 related immunothrombosis. Increased levels of soluble NETs markers are shown to correlate with COVID-19 severity and outcome. However, limited data is available on the impact of drug therapy on NETs level and the possibility to determine NETs in blood smears.

Aims: To determine the possible role of NETs observed in blood smears during COVID-19.

Methods: 46 patients with confirmed COVID-19 (11 non-ICU, 26 ICU, 9 ECMO) and 53 healthy volunteers were studied (independent ethics committee of NMRC PHOI No 3/2020). NETs were investigated in standardized thin blood smears produced of citrated whole blood and stained by May-Grünwald-Giemsa method. NETs percentage to number of neutrophils was calculated (%NETs). %NETs median levels between groups are compared using Mann-Whitney U-Test.

Results: %NETs was 3.3 times higher in COVID-19 patients compared to healthy donors (p<0.0001) and 1.3 times higher in ECMO patients (p<0.0001). Drugs intake was shown to decrease %NETs: tocilizumab – 1.6-fold (p=0.0066); glucocorticoids – 1.2-fold (p=0.00087); omeprazole – 1.3-fold (p<0.0001), antibiotic therapy with any antibiotics – 1.44-fold (p<.0001). Interestingly, levofloxacin showed higher decrease in %NETs – 1.76-fold. %NETs negatively correlated with platelets refractoriness to activation. %NETs and platelets count were analyzed in those 23 patients (13 deceased), who was observed two last days. %NETs was 2 times higher (p=0.47) and the platelets count was 3.3 times lower (p=0.0024) in deceased patients. A negative correlation was found between %NETs and platelets count (Spearman’s correlation R=-0.414; p=.049).

Conclusions: COVID-19 severity and outcome correlated with increased level of NETs, determined in blood smears. Intake of several drugs, known to inhibit NETosis or neutrophil activation, lead to decrease of NETs level. Thrombocytopenia and reduced activation capacity of platelets correlated with NETs level, confirming that NETs and platelets together are involved in coagulopathy in COVID-19.

To cite this abstract in AMA style:

Kassina D, Gur'ev A, Martyanov A, Boldova A, Stepanyan M, An O, Tsarenko S, Ataullakhanov F, Sveshnikova A, Volkov A. Neutrophil Extracellular Traps in COVID-19 Patients Correlates with Therapy, Disease Severity and Mortality [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/neutrophil-extracellular-traps-in-covid-19-patients-correlates-with-therapy-disease-severity-and-mortality/. Accessed May 16, 2022.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/neutrophil-extracellular-traps-in-covid-19-patients-correlates-with-therapy-disease-severity-and-mortality/

Simple Search

Supported By:

Bristol Myers Squibb and Pfizer

ISTH 2021 Congress site

Visit the official web site for the ISTH 2021 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley